Last update 01 Nov 2024

Nanjing KAEDI Biotech, Inc.

Holding Company|
Shanghai Shi, China
|
www.kaedibio.com

Overview

Tags

Endocrinology and Metabolic Disease
Digestive System Disorders
Neoplasms
Autologous CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Neoplasms1
Top 5 Drug TypeCount
Autologous CAR-T1
Top 5 TargetCount
CLDN18.2 x GluN2B x NAMPT x NKG2D x NMDA receptor1

Related

1
Drugs associated with Nanjing KAEDI Biotech, Inc.
KD-496
Target
CLDN18.2 x GluN2B x NAMPT x NKG2D x NMDA receptor
Mechanism
CLDN18.2 inhibitors [+6]
Active Org.
Nanjing KAEDI Biotech, Inc. [+2]
Originator Org.
Nanjing KAEDI Biotech, Inc.Nanjing KAEDI Biotech, Inc.
Active Indication
CLDN18.2 positive Solid Tumors [+3]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Nanjing KAEDI Biotech, Inc.
NCT05583201 / RecruitingEarly Phase 1IIT
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
100 Clinical Results associated with Nanjing KAEDI Biotech, Inc.
Login to view more data
0 Patents (Medical) associated with Nanjing KAEDI Biotech, Inc.
Login to view more data
100 Deals associated with Nanjing KAEDI Biotech, Inc.
Login to view more data
100 Translational Medicine associated with Nanjing KAEDI Biotech, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
KD-496
 ( CLDN18.2 x GluN2B x NAMPT x NKG2D x NMDA receptor )		CLDN18.2 positive Solid Tumors
More
Phase 1 Clinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free